NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NovaBay Pharmaceuticals reports strong Q2 performance amidst market expansion

NovaBay Pharmaceuticals demonstrated strong performance in Q2 2024, driven by growth in eyecare products and improved gross margin.
While facing challenges such as net losses and low cash reserves, the company is focused on strategic transactions and market opportunities.
With a clear focus on the U.S. dry eye market and sales optimization, NovaBay is poised for continued growth and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals Expands Avenova's Geographic Reach to Australia with New Exclusive Distribution Agreement

NovaBay Pharmaceuticals Expands Avenova's Geographic Reach to Australia with New Exclusive Distribution Agreement

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q3 2020 Results - Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2020 and provides a business update. “This is an exceptionally exciting time at NovaBay as Avenova unit sales set a new quarterly record and we prepare for the consumer launch of CelleRx Clinical Reset into the beauty market,” said Justin Hall, President and CEO of NovaBay Pharmaceuticals. “Product revenue for the quarter increased

NovaBay Pharmaceuticals Reports Third Quarter 2020 Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #CelleRx--NovaBay Launches CelleRx Clinical Reset and enters the beauty market

NovaBay Announces Consumer Launch of CelleRx® Clinical Reset™

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals to announce third quarter 2020 financial results on November 12

NovaBay Pharmaceuticals to Hold Third Quarter 2020 Conference Call on November 12

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay regains compliance with NYSE American listing standards

NovaBay Pharmaceuticals Regains Compliance with NYSE American Listing Standards

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces expanded Avenova® consumer marketing programs designed to generate greater awareness of its antimicrobial lid and lash spray and promote online sales. NovaBay has engaged PartnerCentric, Inc. for affiliate marketing programs and HVM Communications for enhanced public relations featuring consumer-oriented, lifestyle messaging. “Since engaging PartnerCentric only days ago we are already having succe

NovaBay Pharmaceuticals Expands Avenova® Consumer Marketing through Affiliate Programs and Enhanced Lifestyle Public Relations

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay® Pharmaceuticals, Inc.

NovaBay Announces that Avenova is Now Available with “Subscribe & Save”

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc.

NovaBay Appoints CEO Justin Hall to its Board of Directors

NovaBay Pharmaceuticals, Inc. (NYSE: NBY) shares are trading higher after the company announced the launch of its Avenova Facial Sanitizer on Walmart Inc.

Why NovaBay's Stock Is Trading Higher Today

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay expands Avenova's online distribution to include Walmart.com

NovaBay Expands Avenova’s Online Distribution

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q2 2020 Results - Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay reports second quarter 2020 financial results.

NovaBay Pharmaceuticals Reports Second Quarter 2020 Financial Results

Digital Ally Inc

Foresight Autonomous Hlds

iBio

Exela Technologies

XpresSpa Group

While penny stocks carry a high degree of risk, they could be a good place to look for value in today's market for investors that are willing to make short-term trades. These seven have potential catalysts on the horizon that make them worth considering.

7 Penny Stocks for the Valiant Investor

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay Pharmaceuticals to Hold Second Quarter 2020 Conference Call on August 6

NovaBay Pharmaceuticals to Hold Second Quarter 2020 Conference Call on August 6

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q1 2020 Results - Earnings Call Transcript

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q4 2019 Results - Earnings Call Transcript

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q3 2019 Results - Earnings Call Transcript

NovaBay Pharmaceuticals' (NBY) CEO Justin Hall on Q2 2019 Results - Earnings Call Transcript

NovaBay Pharmaceuticals (NYSE: NBY) shares are trading higher after the company said its plan of compliance was accepted by the New York Stock Exchange.

NovaBay Trades Higher After Compliance Plan Accepted By NYSE

The 875-percent rally that propelled NovaBay Pharmaceuticals, Inc. (NYSE: NBY) shares from under 50 cents to over $3 Monday came on news of the micro-cap biotech making its Avenova eyecare product available through Amazon.com, Inc.

What You Should Know About The Eye Care Product That Sent NovaBay Shares Soaring Nearly 900%

NovaBay Pharmaceuticals Inc.'s stock NBY, +484.91% has blasted off to a more-than 6-fold gain in extremely active Monday afternoon trading, after the specialty pharmaceutical company said its Avenova eye-care product is available to buy without a prescription on Amazon.com.

NovaBay's stock halted for volatility 18 times as it rockets 557%

NovaBay Pharmaceuticals Inc. (NYSE: NBY) shares absolutely exploded on Monday after the company announced that its eye care treatment would be readily available on Amazon.

Why NovaBay Pharma Shares Absolutely Exploded

Shares of nano-cap biopharmaceutical company NovaBay Pharmaceuticals, Inc. (NYSE: NBY) skyrocketed 220 percent Monday morning after the company inked an agreement to sell its eye care product on Amazon.com, Inc.

NovaBay Pharma's Stock Is Up 200% After Amazon Deal

Shares of NovaBay Pharmaceuticals Inc. nearly doubled in active premarket trade Monday, after the biopharmaceutical company said its Avenova eye-care product is now available without a prescription on Amazon.com AMZN, +2.83% through its new direct-to-consumer online channel.

News for NovaBay Pharmaceuticals Stock (NBY)